Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Phase II Reactions: Acetylation Reactions01:24

Phase II Reactions: Acetylation Reactions

229
Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
229
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

869
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
869
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

667
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
667
Inflammation01:38

Inflammation

53.4K
Overview
53.4K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

675
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
675

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extraintestinal Manifestations of Inflammatory Bowel Disease: A Focus on Kidney Complications.

International journal of molecular sciences·2026
Same author

Granulosa cell dysfunction is associated with MCU-mediated mitochondrial calcium dyshomeostasis and reduced AKT phosphorylation in porcine cystic follicles.

Theriogenology·2026
Same author

The selective cognitive benefits of long-term Tai Chi practice on executive function of students: a study on young adults.

Frontiers in psychology·2026
Same author

LncRNA ZFAS1 Promotes Alveolar Bone Resorption by Enhancing Osteoclastogenesis in Periodontitis.

Journal of cellular physiology·2026
Same author

Rodent Models for Atherosclerosis.

International journal of molecular sciences·2026
Same author

Growth, spectroscopy, and ∼3 <b>μ</b>m continuous-wave laser oscillation of Ho,Pr:YGG crystal.

Optics express·2025

Related Experiment Video

Updated: Jul 7, 2025

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.3K

N-Acetylcysteine and Atherosclerosis: Promises and Challenges.

Yuqi Cui1, Qiang Zhu2, Hong Hao2

  • 1Department of Geriatrics, Donald W. Reynolds Institute on Aging, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA.

Antioxidants (Basel, Switzerland)
|December 23, 2023
PubMed
Summary

N-acetylcysteine (NAC) shows promise in reducing atherosclerosis development and progression, particularly due to its antioxidant and anti-inflammatory properties. However, clinical evidence in patients remains limited and inconsistent, requiring further investigation.

Keywords:
N-acetylcysteineantioxidantatherosclerosisinflammationoxidative stress

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

10.1K

Related Experiment Videos

Last Updated: Jul 7, 2025

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.3K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

10.1K

Area of Science:

  • Cardiovascular Science
  • Pharmacology
  • Biochemistry

Background:

  • Atherosclerosis is a major cause of cardiovascular disease, driven by complex mechanisms involving inflammation and oxidative stress.
  • N-acetylcysteine (NAC) is a known mucolytic and antidote with a strong safety profile.
  • NAC exhibits antioxidant and anti-inflammatory effects by boosting glutathione and inhibiting inflammatory cytokines.

Purpose of the Study:

  • To review preclinical and clinical data on N-acetylcysteine's effects on atherosclerosis.
  • To explore NAC's mechanisms of action in atherosclerosis.
  • To identify challenges in current research.

Main Methods:

  • Systematic review of animal studies on NAC and atherosclerosis.
  • Analysis of clinical trial data investigating NAC in atherosclerosis patients.
  • Examination of molecular pathways involved in NAC's effects.

Main Results:

  • Animal studies consistently show NAC reduces atherosclerosis development and progression.
  • Clinical study data on NAC's efficacy in atherosclerosis patients is limited and shows inconsistent outcomes.
  • NAC's mechanisms involve increasing glutathione and reducing inflammatory mediators.

Conclusions:

  • NAC demonstrates significant potential in preclinical models of atherosclerosis.
  • Further well-designed clinical trials are needed to confirm NAC's efficacy and optimal use in patients with atherosclerosis.
  • Understanding NAC's clinical impact requires addressing current research limitations.